|
font size
The second quarter saw the markets come roaring back as the Dow Jones Industrial Average rose 12 percent and the Nasdaq Composite Index soared 20 percent. The biotech sector didn’t fare as well, but managed to end the quarter in positive territory as the Burrill Biotech Select Index gained 3 percent. Nevertheless, some biotech stocks, such as Dendreon, showed they could be explosive, while others just seemed to blow up. We spoke to Peter Winter, editor-in-chief of The Burrill Report about the sector’s performance in the second quarter, the financing and dealmaking activity, and what to expect in the second half of 2009.
![]()
Business
Health
Policy / Law
Society
Tech/Innovation
Podcasts
Listen to the latest edition from The Journal of Life Sciences Weekly briefsA round-up of breakthroughs, policy developments and other news reshaping the life sciences landscape.
Podcast
Why We Must Address The Primary Care Crisis for Healthcare Reform to Succeed
By the numbers
Summer Sizzle
|